Phase II Trial of Parathyroid Hormone after Double Umbilical Cord Blood Transplantation

Karen Ballen; Adam M. Mendizabal; Corey Cutler; Ioannis Politikos; Katarzyna Jamieson; Elizabeth J. Shpall; Bimalangshu R. Dey; Eyal Attar; Steven McAfee; Colleen Delaney; Philip McCarthy; Edward D. Ball; Ram Kamble; David Avigan; Richard T. Maziarz; Vincent T. Ho; John Koreth; Edwin Alyea; Robert Soiffer; John R. Wingard; Vicki Boussiotis; Thomas R. Spitzer; Joseph H. Antin

doi:10.1016/j.bbmt.2012.06.016

Phase II Trial of Parathyroid Hormone after Double Umbilical Cord Blood Transplantation

Karen Ballen, Adam M. Mendizabal, Corey Cutler, Ioannis Politikos, Katarzyna Jamieson, Elizabeth J. Shpall, Bimalangshu R. Dey, Eyal Attar, Steven McAfee, Colleen Delaney, Philip McCarthy, Edward D. Ball, Ram Kamble, David Avigan, Richard T. Maziarz, Vincent T. Ho, John Koreth, Edwin Alyea, Robert Soiffer, John R. WingardVicki Boussiotis, Thomas R. Spitzer, Joseph H. Antin

Knight Cancer Institute

Research output: Contribution to journal › Article › peer-review

21 Scopus citations

Abstract

Transplantation of 1 or 2 umbilical cord blood products is a useful alternative stem cell source. However, the limited number of stem cells in each infusion results in slow engraftment. In mouse models, administration of parathyroid hormone (PTH) is an effective way to enhance the ability of limited numbers of hematopoietic stem cells to support hematopoiesis. In this study, patients received either a myeloablative or a reduced-intensity double umbilical cord blood transplantation, followed by PTH at 100 μg/day for 28 days. Thirteen patients (median age, 42 years) were enrolled. All patients engrafted; the median time to neutrophil and platelet engraftment of >20 × 10⁹ cells/L was 30 days and 61 days, respectively. The incidence of grade II-IV acute GVHD was 38.5% at day 100. Four deaths occurred before day 100, prompting early study closure. No patient who received a myeloablative regimen relapsed. Overall survival at 6 months after transplantation was 62%, and disease-free survival at 2 years was 39%. At the dose and schedule studied, there was no evidence that PTH influenced blood count recovery.

Original language	English (US)
Pages (from-to)	1851-1858
Number of pages	8
Journal	Biology of Blood and Marrow Transplantation
Volume	18
Issue number	12
DOIs	https://doi.org/10.1016/j.bbmt.2012.06.016
State	Published - Dec 2012

Keywords

Cord blood
Engraftment
Transplantation

ASJC Scopus subject areas

Hematology
Transplantation

Access to Document

10.1016/j.bbmt.2012.06.016

Cite this

Ballen, K., Mendizabal, A. M., Cutler, C., Politikos, I., Jamieson, K., Shpall, E. J., Dey, B. R., Attar, E., McAfee, S., Delaney, C., McCarthy, P., Ball, E. D., Kamble, R., Avigan, D., Maziarz, R. T., Ho, V. T., Koreth, J., Alyea, E., Soiffer, R., ... Antin, J. H. (2012). Phase II Trial of Parathyroid Hormone after Double Umbilical Cord Blood Transplantation. Biology of Blood and Marrow Transplantation, 18(12), 1851-1858. https://doi.org/10.1016/j.bbmt.2012.06.016

Ballen, K, Mendizabal, AM, Cutler, C, Politikos, I, Jamieson, K, Shpall, EJ, Dey, BR, Attar, E, McAfee, S, Delaney, C, McCarthy, P, Ball, ED, Kamble, R, Avigan, D, Maziarz, RT, Ho, VT, Koreth, J, Alyea, E, Soiffer, R, Wingard, JR, Boussiotis, V, Spitzer, TR & Antin, JH 2012, 'Phase II Trial of Parathyroid Hormone after Double Umbilical Cord Blood Transplantation', Biology of Blood and Marrow Transplantation, vol. 18, no. 12, pp. 1851-1858. https://doi.org/10.1016/j.bbmt.2012.06.016

@article{f341a7d0b86e427d8cae36af787905d6,

title = "Phase II Trial of Parathyroid Hormone after Double Umbilical Cord Blood Transplantation",

abstract = "Transplantation of 1 or 2 umbilical cord blood products is a useful alternative stem cell source. However, the limited number of stem cells in each infusion results in slow engraftment. In mouse models, administration of parathyroid hormone (PTH) is an effective way to enhance the ability of limited numbers of hematopoietic stem cells to support hematopoiesis. In this study, patients received either a myeloablative or a reduced-intensity double umbilical cord blood transplantation, followed by PTH at 100 μg/day for 28 days. Thirteen patients (median age, 42 years) were enrolled. All patients engrafted; the median time to neutrophil and platelet engraftment of >20 × 109 cells/L was 30 days and 61 days, respectively. The incidence of grade II-IV acute GVHD was 38.5% at day 100. Four deaths occurred before day 100, prompting early study closure. No patient who received a myeloablative regimen relapsed. Overall survival at 6 months after transplantation was 62%, and disease-free survival at 2 years was 39%. At the dose and schedule studied, there was no evidence that PTH influenced blood count recovery.",

keywords = "Cord blood, Engraftment, Transplantation",

author = "Karen Ballen and Mendizabal, {Adam M.} and Corey Cutler and Ioannis Politikos and Katarzyna Jamieson and Shpall, {Elizabeth J.} and Dey, {Bimalangshu R.} and Eyal Attar and Steven McAfee and Colleen Delaney and Philip McCarthy and Ball, {Edward D.} and Ram Kamble and David Avigan and Maziarz, {Richard T.} and Ho, {Vincent T.} and John Koreth and Edwin Alyea and Robert Soiffer and Wingard, {John R.} and Vicki Boussiotis and Spitzer, {Thomas R.} and Antin, {Joseph H.}",

year = "2012",

month = dec,

doi = "10.1016/j.bbmt.2012.06.016",

language = "English (US)",

volume = "18",

pages = "1851--1858",

journal = "Biology of Blood and Marrow Transplantation",

issn = "1083-8791",

publisher = "Elsevier Inc.",

number = "12",

}

TY - JOUR

T1 - Phase II Trial of Parathyroid Hormone after Double Umbilical Cord Blood Transplantation

AU - Ballen, Karen

AU - Mendizabal, Adam M.

AU - Cutler, Corey

AU - Politikos, Ioannis

AU - Jamieson, Katarzyna

AU - Shpall, Elizabeth J.

AU - Dey, Bimalangshu R.

AU - Attar, Eyal

AU - McAfee, Steven

AU - Delaney, Colleen

AU - McCarthy, Philip

AU - Ball, Edward D.

AU - Kamble, Ram

AU - Avigan, David

AU - Maziarz, Richard T.

AU - Ho, Vincent T.

AU - Koreth, John

AU - Alyea, Edwin

AU - Soiffer, Robert

AU - Wingard, John R.

AU - Boussiotis, Vicki

AU - Spitzer, Thomas R.

AU - Antin, Joseph H.

PY - 2012/12

Y1 - 2012/12

N2 - Transplantation of 1 or 2 umbilical cord blood products is a useful alternative stem cell source. However, the limited number of stem cells in each infusion results in slow engraftment. In mouse models, administration of parathyroid hormone (PTH) is an effective way to enhance the ability of limited numbers of hematopoietic stem cells to support hematopoiesis. In this study, patients received either a myeloablative or a reduced-intensity double umbilical cord blood transplantation, followed by PTH at 100 μg/day for 28 days. Thirteen patients (median age, 42 years) were enrolled. All patients engrafted; the median time to neutrophil and platelet engraftment of >20 × 109 cells/L was 30 days and 61 days, respectively. The incidence of grade II-IV acute GVHD was 38.5% at day 100. Four deaths occurred before day 100, prompting early study closure. No patient who received a myeloablative regimen relapsed. Overall survival at 6 months after transplantation was 62%, and disease-free survival at 2 years was 39%. At the dose and schedule studied, there was no evidence that PTH influenced blood count recovery.

AB - Transplantation of 1 or 2 umbilical cord blood products is a useful alternative stem cell source. However, the limited number of stem cells in each infusion results in slow engraftment. In mouse models, administration of parathyroid hormone (PTH) is an effective way to enhance the ability of limited numbers of hematopoietic stem cells to support hematopoiesis. In this study, patients received either a myeloablative or a reduced-intensity double umbilical cord blood transplantation, followed by PTH at 100 μg/day for 28 days. Thirteen patients (median age, 42 years) were enrolled. All patients engrafted; the median time to neutrophil and platelet engraftment of >20 × 109 cells/L was 30 days and 61 days, respectively. The incidence of grade II-IV acute GVHD was 38.5% at day 100. Four deaths occurred before day 100, prompting early study closure. No patient who received a myeloablative regimen relapsed. Overall survival at 6 months after transplantation was 62%, and disease-free survival at 2 years was 39%. At the dose and schedule studied, there was no evidence that PTH influenced blood count recovery.

KW - Cord blood

KW - Engraftment

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=84869087516&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869087516&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2012.06.016

DO - 10.1016/j.bbmt.2012.06.016

M3 - Article

C2 - 22766223

AN - SCOPUS:84869087516

SN - 1083-8791

VL - 18

SP - 1851

EP - 1858

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

IS - 12

ER -

Phase II Trial of Parathyroid Hormone after Double Umbilical Cord Blood Transplantation

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this